“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

Putting an end to speculation over US President Donald Trump’s health, the White House has announced that the 79-year-old is in “excellent health”.

Trump underwent his annual medical examination at Walter Reed National Military Medical Center on May 26.

"President Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function," Dr. Sean Barbabella, physician to the president, wrote in the memo, released late Friday evening.

He added that Trump is "fully fit to carry out all duties of the Commander-in-Chief and Head of State."

Trump’s health became a major subject of discussion after photographs at times showed swollen ankles, bruised hands, and a blotchy neck. He has been spotted several times with slurred speech and naps during official meetings.

Shortly after the examination, Trump said that "everything checked out perfectly."

Trump, who turns 80 in June, is the oldest person to assume the presidency. He frequently portrays himself as more energetic and fitter than Joe Biden, his Democratic predecessor, who left office last year at age 82 after facing questions about his fitness for the job.

Barbabella described the assessment as a “comprehensive preventive evaluation,” which included a thorough review of all diagnostic studies and laboratory testing conducted over the past year.

It also included “consultations with twenty-two specialty providers from multiple academic institutions. All aspects of the assessment were performed in accordance with US Preventive Services Task Force recommendations,” he said in the memo.

Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation

Diagnostic Summary

The President’s diagnostic summary showed:

• Vision is normal.
• Hearing is intact, and teeth are in very good condition.
• The thyroid and lymph nodes are normal. An ultrasound of the carotid arteries showed normal results.
• The lungs and chest demonstrated no abnormalities.
• Coronary CT angiography demonstrated no arterial obstruction or structural abnormalities of the heart or major vessels.
• An echocardiogram showed no abnormalities. Cardiac function is normal, and circulation to the extremities remains intact.
• Gastrointestinal/abdominal and genitourinary examinations were normal.
• Slight lower leg swelling was noted, with improvement from last year.

Barbabella further said that the medical test also evaluated his hands and “revealed ecchymosis (bruising), consistent with minor soft tissue irritation related to frequent handshaking in the setting of aspirin use for cardiovascular prevention". He added that it is “a common and benign effect of aspirin therapy.”

The examination also found no “suspicious lesions or concerning growths.”

Neurological Health

Read More: Was Trump Sleeping During Oval Office Event? White House Reacts

The President's neurological condition was significantly targeted, with many doctors pointing out that he's suffering from dementia. But the test results, authorized by the President for public release, revealed him to be in “normal mental status".

Further, it showed that his "cranial nerves are intact", and he also has "normal motor strength, sensation, reflexes, gait, and balance.”

Trump also completed the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) screenings for depression and anxiety, both of which were "normal".

Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.

Lab Results

Comprehensive laboratory evaluation, including a complete blood count, comprehensive metabolic panel, coagulation profile, D-dimer, B-type natriuretic peptide, and cardiac biomarkers, remained within normal limits, Barbabella said.

India’s Ministry of Health and Family Welfare (MoHFW) has released the National Family Health Survey-6 (NFHS-6), showing major improvements in maternal healthcare, nutrition, immunization, and family planning across the country.

The nationwide survey, which covered nearly 6.79 lakh households across 715 districts, highlighted stronger healthcare access and improved outcomes for women and children in the country.

Key Findings of NFHS-6

The NFHS-6 was conducted during 2023-24 by MoHFW with the International Institute for Population Sciences (IIPS), Mumbai as the nodal agency.

Maternal Care

NFHS-6 recorded notable gains in maternal and child healthcare services nationwide. Nearly 96 per cent of pregnant women received antenatal care (ANC), while mothers receiving ANC during the first trimester increased from 70.0 per cent to 76.2 per cent.

The percentage of mothers receiving at least four ANC visits also rose from 58.5 per cent to 65.2 per cent, reflecting improved continuity of maternal healthcare services.

Institutional deliveries increased from 88.6 per cent to 90.6 per cent, bringing India closer to universal institutional delivery coverage.

Maternal nutrition indicators also improved significantly. Women consuming iron folic acid supplements for 100 days or more during pregnancy increased from 44.1 per cent to 54.9 per cent. Those consuming supplements for 180 days or more rose from 26.0 per cent to 37.8 per cent.

Family Planning

India’s Total Fertility Rate (TFR) remained stable at 2.0, while the Contraceptive Prevalence Rate (CPR) increased from 66.7 per cent to 69.1 per cent.

The findings reflect improved access to family planning services and the continued impact of government programs, including Mission Parivar Vikas.

Child Immunization

India also recorded progress towards universal immunization coverage. Full vaccination coverage among children aged 12-23 months increased from 83.8 per cent to 87.1 per cent based on vaccination cards.

More than 95 per cent of children received vaccinations through public health facilities, highlighting continued trust in the public healthcare system.

Coverage of major vaccines improved significantly. Rotavirus vaccination coverage surged from 36.4 per cent to 85.4 per cent, while coverage of the second dose of measles-containing vaccine increased from 58.6 per cent to 71.8 per cent.

The survey also found improvement in child health indicators. Symptoms of acute respiratory infection (ARI) among children declined from 2.8 per cent to 1.9 per cent, while severe diarrhea prevalence fell to 0.5 per cent.

The gains were attributed to stronger last-mile healthcare delivery, improved cold chain systems, digital tracking through U-WIN, and active community participation under the Universal Immunization Program.

Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained

Child Nutrition Outcomes

NFHS-6 also reported encouraging progress in child nutrition indicators. More than 95 per cent of children under six months were breastfed during the survey period. The percentage of children breastfed within one hour of birth increased from 41.8 per cent to 50.1 per cent.

Stunting among children under five years declined sharply from 35.5 per cent to 29.3 per cent, indicating improvement in long-term nutritional outcomes.

Severe wasting declined from 7.7 per cent to 5.2 per cent, while underweight prevalence among children under five registered a marginal decline from 32.1 per cent to 31.8 per cent.

Infant and young child feeding practices also improved. Children aged 6-8 months receiving solid or semi-solid food along with breastmilk increased from 45.9 per cent to 59.5 per cent.

Amid the ongoing deadly Ebola outbreak, the World Health Organization (WHO) has identified experimental treatments and vaccine candidates for the Bundibugyo strain, which currently has no approved vaccine or antiviral treatment.

The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with:

• Mapp Biopharmaceutical's MBP134
• Regeneron’s maftivimab
• Gilead Sciences’ antiviral remdesivir

In addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir.

The advisory groups recommended that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.

Preventive Therapies, Vaccine Candidates

Beyond treatment, the WHO also proposed therapies for the prevention of Bundibugyo cases.

• For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate.

• The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate.

The development of the vaccine is expected to take approximately 7–9 months before it can be assessed through clinical trials for its ability to prevent Bundibugyo disease (BDV).

• Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.

• The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.

The WHO stated that Ervebo should not be used outside carefully designed research settings so that its performance against Bundibugyo disease can be properly assessed.

Meanwhile, Regeneron said in a statement that supplies of maftivimab are already available in the Democratic Republic of Congo, if the WHO decides to utilize the treatment immediately or include it as part of additional studies.

Read More: Donald Trump Says Health Check-Up Went 'Perfectly'

Russian Vaccine For New Strain

Meanwhile, Russia has claimed that its scientists have developed a novel vaccine against a new Ebola strain.

According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".

It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.

The rare Bundibugyo strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.